IPD's first nanoparticle vaccine

Message boards : News : IPD's first nanoparticle vaccine

To post messages, you must log in.

AuthorMessage
Admin
Project administrator

Send message
Joined: 1 Jul 05
Posts: 5279
Credit: 0
RAC: 0
Message 90498 - Posted: 8 Mar 2019, 18:51:56 UTC
Last modified: 8 Mar 2019, 18:52:58 UTC



Researchers in the King lab, an affiliate of the Institute for Protein Design, published a report in Cell describing a computer-designed nanoparticle vaccine targeting respiratory syncytial virus (RSV). Although Rosetta@home was not directly used for this study, Rosetta@home volunteers provided computing for related research and development.

From IPD news:

Millions of children will visit hospitals this year, sickened by RSV. Infection is usually mild, causing only fevers, runny noses and frightened parents. But, in severe cases, barking coughs and painful wheezing can indicate serious respiratory complications, including bronchiolitis and pneumonia.

RSV is the primary cause of pneumonia in children under one and is therefore the leading cause of infant mortality worldwide after malaria. Although virtually every child on Earth will get RSV before the age of three, an estimated 99 percent of RSV deaths occur in developing countries. Despite substantial effort, there is not yet a safe and effective vaccine.

Today, an international team of scientists co-led by researchers at the IPD report in Cell a first-of-its-kind vaccine candidate for RSV. It elicits broadly neutralizing antibodies against respiratory syncytial virus in mice and monkeys, paving the way for human clinical trials.
ID: 90498 · Rating: 0 · rate: Rate + / Rate - Report as offensive    Reply Quote
Falconet

Send message
Joined: 9 Mar 09
Posts: 110
Credit: 234,514
RAC: 428
Message 99070 - Posted: 21 Sep 2020, 18:04:44 UTC - in response to Message 90498.  
Last modified: 21 Sep 2020, 18:04:56 UTC

Per the IPD's annual report, this vaccine candidate is planned to enter into a Phase 1 clinical trial in April 2021.

"The IPD has transferred methods for producing and characterizing it to the NIH, where it is currently being manufactured for planned entry into a Phase I clinical trial in April 2021"

Page 7.
ID: 99070 · Rating: 0 · rate: Rate + / Rate - Report as offensive    Reply Quote
Falconet

Send message
Joined: 9 Mar 09
Posts: 110
Credit: 234,514
RAC: 428
Message 99081 - Posted: 22 Sep 2020, 0:00:29 UTC - in response to Message 99070.  
Last modified: 22 Sep 2020, 0:04:06 UTC

Correct version of my comment:

This vaccine is planned to begin a Phase 1 clinical trial in the first quarter of 2021.
See page 6 of the Annual IPD report
ID: 99081 · Rating: 0 · rate: Rate + / Rate - Report as offensive    Reply Quote

Message boards : News : IPD's first nanoparticle vaccine



©2020 University of Washington
https://www.bakerlab.org